JP2023500032A5 - - Google Patents

Info

Publication number
JP2023500032A5
JP2023500032A5 JP2022521146A JP2022521146A JP2023500032A5 JP 2023500032 A5 JP2023500032 A5 JP 2023500032A5 JP 2022521146 A JP2022521146 A JP 2022521146A JP 2022521146 A JP2022521146 A JP 2022521146A JP 2023500032 A5 JP2023500032 A5 JP 2023500032A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glp
composition according
receptor agonist
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500032A (ja
JP7670698B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081087 external-priority patent/WO2021089678A1/en
Publication of JP2023500032A publication Critical patent/JP2023500032A/ja
Publication of JP2023500032A5 publication Critical patent/JP2023500032A5/ja
Priority to JP2024211204A priority Critical patent/JP2025027130A/ja
Application granted granted Critical
Publication of JP7670698B2 publication Critical patent/JP7670698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521146A 2019-11-06 2020-11-05 認知症におけるｇｌｐ－１受容体作動薬 Active JP7670698B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024211204A JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207501.8 2019-11-06
EP19207501 2019-11-06
EP20186623 2020-07-20
EP20186623.3 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024211204A Division JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Publications (3)

Publication Number Publication Date
JP2023500032A JP2023500032A (ja) 2023-01-04
JP2023500032A5 true JP2023500032A5 (https=) 2023-11-14
JP7670698B2 JP7670698B2 (ja) 2025-04-30

Family

ID=73172681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521146A Active JP7670698B2 (ja) 2019-11-06 2020-11-05 認知症におけるｇｌｐ－１受容体作動薬
JP2024211204A Pending JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024211204A Pending JP2025027130A (ja) 2019-11-06 2024-12-04 認知症におけるｇｌｐ－１受容体作動薬

Country Status (19)

Country Link
US (4) US20220280612A1 (https=)
EP (2) EP4414031A3 (https=)
JP (2) JP7670698B2 (https=)
KR (1) KR20220110731A (https=)
CN (1) CN114728042A (https=)
AU (1) AU2020377469A1 (https=)
BR (1) BR112022007721A2 (https=)
CA (1) CA3154744A1 (https=)
ES (1) ES2984177T3 (https=)
HR (1) HRP20241052T1 (https=)
HU (1) HUE067514T2 (https=)
IL (1) IL291876A (https=)
MA (1) MA57599B1 (https=)
MX (1) MX2022004779A (https=)
PH (1) PH12022550842A1 (https=)
PL (1) PL4054620T3 (https=)
RS (1) RS65780B1 (https=)
TW (1) TWI890704B (https=)
WO (1) WO2021089678A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
KR20240123816A (ko) 2021-12-02 2024-08-14 쾨벤하운스 유니버시테트 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
EP2866825B1 (en) * 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Similar Documents

Publication Publication Date Title
JP2023500032A5 (https=)
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
JP6353577B2 (ja) 組み合わせ組成物
ES2830447T3 (es) Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
TWI633887B (zh) 用於預防及／或治療多囊性腎臟病之藥物
JP2009514874A5 (https=)
EP1750677B1 (en) Oral therapeutic compound delivery system
HRP20241052T1 (hr) Semaglutid, namijenjen liječenju alzheimerove demencije
JP2024503265A5 (https=)
JP2023552700A5 (https=)
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
IL265761B1 (en) Oral terlipressin compositions for use in treatment of ascites
ES2604254T3 (es) Combinaciones de flurbiprofeno de liberación controlada y relajante muscular
JP2016505050A5 (https=)
JP2009242360A (ja) 経口用の慢性疼痛予防または治療剤
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
JP2019507786A5 (https=)
RU2005105691A (ru) Пероральное введение кальцитонина
JP5053665B2 (ja) 催眠用医薬組成物
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2023520703A5 (https=)
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
JP2021530568A5 (https=)
EP4420660A1 (en) Use of edaravone in treatment of autism spectrum disorder
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна